Skip to main content

Table 2 Demographic and clinical characteristics for patients entering the open-label versus double-blind phasea

From: Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience

Characteristic Open-label phase
(n = 67)
Double-blind phase
(n = 29)
Age (years)
 Mean (SD) 58.7 (12.4) 55.3 (14.0)
 Median (range) 60 (21–79) 56 (21–74)
Sex, n (%)
 Male 23 (34.3) 10 (34.5)
 Female 44 (65.7) 19 (65.5)
Height (cm)   
 Mean (SD) 167.3 (9.4) 167.3 (9.0)
 Median (range) 165.0 (144–193) 165.0 (144–186)
Weight (kg)
 Mean (SD) 74.8 (14.3) 76.1 (13.4)
 Median (range) 73.0 (47–107) 74.0 (55–107)
BMI (kg/m2)
 Mean (SD) 26.6 (3.9) 27.1 (3.8)
 Median (range) 25.9 (19–35) 27.2 (22–33)
Race, n (%)
 White 64 (95.5) 28 (96.6)
 African American/African heritage 1 (1.5) 1 (3.4)
 Mixed race 2 (3.0) 0
TN duration (years), median (range) 6 (0–35) 6 (1–17)
Number of previous therapies for TN, median (range) 2 (1–25) 1 (1–6)
Anatomical site of TN pain, n (%)   
 First branch 1 (2) 1 (3)
 Second branch 17 (25) 9 (31)
 Third branch 17 (25) 7 (24)
 First and second branches 5 (8) 3 (10)
 First, second, and third branches 7 (10) 2 (7)
 Second and third branches 20 (30) 7 (24)
  1. BMI body mass index, SD standard deviation, TN trigeminal neuralgia
  2. aFull study population published in [16]